| 4.695 -0.115 (-2.39%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.22 | 1-year : | 6.73 |
| Resists | First : | 5.33 | Second : | 5.76 |
| Pivot price | 4.94 |
|||
| Supports | First : | 4.62 | Second : | 3.84 |
| MAs | MA(5) : | 4.8 |
MA(20) : | 5 |
| MA(100) : | 6.11 |
MA(250) : | 6.1  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.9 |
D(3) : | 16.7 |
| RSI | RSI(14): 38.6 |
|||
| 52-week | High : | 8.73 | Low : | 3.93 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ UNCY ] has closed above bottom band by 19.9%. Bollinger Bands are 47.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.86 - 4.89 | 4.89 - 4.9 |
| Low: | 4.59 - 4.63 | 4.63 - 4.65 |
| Close: | 4.65 - 4.7 | 4.7 - 4.74 |
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Sat, 26 Sep 2026
Shareholders of Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights Before November 2, 2026 – Contact Levi & Korsinsky - ACCESS Newswire
Fri, 25 Sep 2026
UNCY Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
Fri, 25 Sep 2026
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Thu, 24 Sep 2026
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) - The National Law Review
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 42.2 (%) |
| Shares Short | 4,150 (K) |
| Shares Short P.Month | 4,940 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.6 % |
| Return on Equity (ttm) | -101.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -2.69 |
| PEG Ratio | 0 |
| Price to Book value | 2.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|